Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02238496 · ClinicalTrials.gov registry record · Phase 1
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
A Phase 1 study, sponsored by Andrew B Lassman, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02238496: Completed Phase 1 study, sponsored by Andrew B Lassman, MD.
NCT02238496 is a Phase 1 study that has completed, run by Andrew B Lassman, MD. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02238496, a Phase 1 study, has completed, sponsored by Andrew B Lassman, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow. Research suggests that combined treatment with both drugs is better than either alone, and that it is reasonably safe.
Primary Outcome
Clinical Benefit Rate is defined as the radiographic response rate plus 6-month progression-free survival (PFS) rate.
Interventions
- DRUG Temsirolimus
- PROCEDURE Cytoreductive surgery
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12-08 |
| Est. Completion | 2021-02-14 |
| Phase | Phase 1 |
What the finished NCT02238496 record still lists
NCT02238496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Temsirolimus is the first listed.
NCT02238496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02238496 about?
NCT02238496 is a clinical study titled "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas". The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kid...
What is the current status of trial NCT02238496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12-08. Estimated completion is 2021-02-14.
What interventions are being tested in trial NCT02238496?
The interventions under investigation include: Temsirolimus (DRUG), Cytoreductive surgery (PROCEDURE), Perifosine (DRUG).
Who is sponsoring clinical trial NCT02238496?
This trial is sponsored by Andrew B Lassman, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02238496's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI